Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 June 2019

Cumulative for April, May and June 2019

New Zealand Government

PHARMAC
Pharmaceutical Management Agency

Contents

Summary of decisions
EFFECTIVE 1 JUNE 2019

- Dasatinib (Sprycel) tab 100 mg – delisted 1 June 2019
- Dasatinib (Sprycel) tab 20 mg, 50 mg and 70 mg – amended restriction criteria
- Dosulepin [dothiepin] hydrochloride tab 75 mg and cap 25 mg – restriction added and to be delisted from 1 January 2020 (cap 25 mg) and 1 August 2020 (tab 75 mg)
- Factor eight inhibitor bypassing fraction (FEIBA NF) inj 500 U – price decrease
- Insulin pen needles 29 g x 12.7 mm, 31 g × 5 mm, 31 g × 8 mm and 32 g × 4 mm (B-D Micro-Fine) and 31 g × 6 mm (ABM) – moved to addendum in Part III
- Insulin syringe, disposable with attached needle syringe 0.3 ml with 29 g × 12.7 mm needle, 0.5 ml with 29 g × 12.7 mm needle and 1 ml with 29 g × 12.7 mm needle (B-D Ultra Fine) and syringe 0.3 ml with 31 g × 8 mm needle, 0.5 ml with 31 g × 8 mm needle and 1 ml with 31 g × 8 mm needle (B-D Ultra Fine II) – moved to addendum in Part III
- Labetalol (Presolol) tab 100 mg and 200 mg – new listing
- Levomepromazine (Nozinan) tab 25 mg and 100 mg – new listing
- Lidocaine [lignocaine] hydrochloride (Cathejell) gel 2%, 10 ml urethral syringe – price decrease and addition of HSS
- Lidocaine [lignocaine] hydrochloride (Pfizer) gel 2%, 10 ml urethral syringe – to be delisted 1 November 2019
- Methadone hydrochloride (Methatabs) tab 5 mg – new listing
- Methadone hydrochloride (Methatabs) tab 5 mg-bottle pack – price decrease, amended presentation and to be delisted 1 December 2019
- Roxithromycin (Arrow-Roxithromycin) tab 150 mg and 300 mg – price increase and addition of HSS

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 June 2019

BLOOD AND BLOOD FORMING ORGANS

27 FACTOR EIGHT INHIBITOR BYPASSING FRACTION (↓ price)

➔ Inj 500 U	1,315.00	1	FEIBA NF

CARDIOVASCULAR SYSTEM

40 LABETALOL (new listing)

Tab 100 mg	11.36	100	Presolol
Tab 200 mg	29.74	100	Presolol

INFECTIONS

75 ROXITHROMYCIN (↑ price and addition of HSS)

Tab 150 mg – **1% DV Sep-19 to 2022**	8.28	50	**Arrow-Roxithromycin**
Tab 300 mg – **1% DV Sep-19 to 2022**	16.33	50	**Arrow-Roxithromycin**

NERVOUS SYSTEM

106 LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (↓ price and addition of HSS)

Gel 2%, 10 ml urethral syringe – **1% DV Nov-19 to 2022**	105.00	25	**Cathejell**

Note – Pfizer gel 2%, 10 ml urethral syringe to be delisted from 1 November 2019.

108 METHADONE HYDROCHLORIDE (new listing)

Tab 5 mg – **1% DV Sep-19 to 2022**	1.40	10	**Methatabs**

108 METHADONE HYDROCHLORIDE (↓ price, amended presentation and delisting)

Tab 5 mg – **bottle pack**	1.40	10	Methatabs

Note – Methatabs tab 5 mg – bottle pack to be delisted from 1 December 2019.

111 DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – **Restricted: For continuation only** (restriction added)

Tab 75 mg	11.19	100	Dopress
Cap 25 mg	6.45	100	Dopress

Note – Dopress tab 75 mg to be delisted from 1 August 2020 and Dopress cap 25 mg to be delisted from 1 January 2020.

118 LEVOMEPROMAZINE (new listing)

Tab 25 mg – **1% DV Sep-19 to 2022**	16.10	100	**Nozinan**
Tab 100 mg – **1% DV Sep-19 to 2022**	41.75	100	**Nozinan**

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

136 DASATINIB (delisted)

➔ Tab 100 mg	6,214.20	30	Sprycel

Note – Sprycel tab 100 mg delisted from 1 June 2019.

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 June 2019 (continued)

136 DASATINIB (amended restriction criteria)

➔ Tab 20 mg	3,774.06	60	Sprycel
➔ Tab 50 mg	6,214.20	60	Sprycel
➔ Tab 70 mg	7,692.58	60	Sprycel

Restricted
Initiation
~~For use in patients with approval from the CML/GIST Co-ordinator.~~
Haematologist or any relevant practitioner on the recommendation of a haematologist
Re-assessment required after 6 months
Any of the following:

1 Both:
- **1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and**
- **1.2 Maximum dose of 140 mg/day; or**

2 Both:
- **2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and**
- **2.2 Maximum dose of 140 mg/day; or**

3 All of the following:
- **3.1 The patient has a diagnosis of CML in chronic phase; and**
- **3.2 Maximum dose of 100 mg/day; and**
- **3.3 Any of the following:**
  - **3.3.1 Patient has documented treatment failure* with imatinib; or**
  - **3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or**
  - **3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or**
  - **3.3.4 Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol.**

Continuation
Haematologist or any relevant practitioner on the recommendation of a haematologist
Re-assessment required after 6 months
All of the following:

1 Lack of treatment failure while on dasatinib*; and
2 Dasatinib treatment remains appropriate and the patient is benefiting from treatment; and
3 Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up https://www.cancertrialsnz.ac.nz/kiss/

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 June 2019 (continued)

OPTIONAL PHARMACEUTICALS

237	INSULIN PEN NEEDLES (moved to addendum in Part III)			
	29 g × 12.7 mm	10.50	100	B-D Micro-Fine
	31 g × 5 mm	11.75	100	B-D Micro-Fine
	31 g × 6 mm	10.50	100	ABM
	31 g × 8 mm	10.50	100	B-D Micro-Fine
	32 g × 4 mm	10.50	100	B-D Micro-Fine
237	INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE (moved to addendum in Part III)			
	Syringe 0.3 ml with 29 g × 12.7 mm needle	13.00	100	B-D Ultra Fine
	Syringe 0.3 ml with 31 g × 8 mm needle	13.00	100	B-D Ultra Fine II
	Syringe 0.5 ml with 29 g × 12.7 mm needle	13.00	100	B-D Ultra Fine
	Syringe 0.5 ml with 31 g × 8 mm needle	13.00	100	B-D Ultra Fine II
	Syringe 1 ml with 29 g × 12.7 mm needle	13.00	100	B-D Ultra Fine
	Syringe 1 ml with 31 g × 8 mm needle	13.00	100	B-D Ultra Fine II

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 May 2019

ALIMENTARY TRACT AND METABOLISM

11 MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE (addition of HSS)
Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet

– 1% DV Aug-19 to 2022	14.31	4	**Klean Prep**

18 MAGNESIUM AMINO ACID CHELATE (new listing)
Cap 750 mg (150 mg elemental)

18 MAGNESIUM OXIDE WITH MAGNESIUM ASPARTATE, MAGNESIUM AMINO ACID CHELATE AND MAGNESIUM CITRATE (new listing)
Cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium)

20 RETINOL (new listing)
Oral liq 5,000 iu per drop, 30 ml

BLOOD AND BLOOD FORMING ORGANS

27 EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] (new listing)

➔ Inj 250 iu vial	612.50	1	Alprolix
➔ Inj 500 iu vial	1,225.00	1	Alprolix
➔ Inj 1,000 iu vial	2,450.00	1	Alprolix
➔ Inj 2,000 iu vial	4,900.00	1	Alprolix
➔ Inj 3,000 iu vial	7,350.00	1	Alprolix

Restricted
Initiation
For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

27 EPTACOG ALFA [RECOMBINANT FACTOR VIIA] (amended restriction criteria)

➔ Inj 1 mg syringe	1,178.30	1	NovoSeven RT
➔ Inj 2 mg syringe	2,356.60	1	NovoSeven RT
➔ Inj 5 mg syringe	5,891.50	1	NovoSeven RT
➔ Inj 8 mg syringe	9,426.40	1	NovoSeven RT

Restricted
Initiation
~~When used in the treatment of haemophilia, access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group~~.
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 May 2019 (continued)

27 FACTOR EIGHT INHIBITOR BYPASSING FRACTION (↓ price and amended restriction criteria)

➔ Inj 500 U	1,315.50	1	FEIBA NF
➔ Inj 1,000 U	2,630.00	1	FEIBA NF
➔ Inj 2,500 U	6,575.00	1	FEIBA NF

Restricted
Initiation
~~When used in the treatment of haemophilia, access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.~~
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

28 MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] (amended restriction criteria)

➔ Inj 250 iu prefilled syringe	210.00	1	Xyntha
➔ Inj 500 iu prefilled syringe	420.00	1	Xyntha
➔ Inj 1,000 iu prefilled syringe	840.00	1	Xyntha
➔ Inj 2,000 iu prefilled syringe	1,680.00	1	Xyntha
➔ Inj 3,000 iu prefilled syringe	2,520.00	1	Xyntha

Restricted
Initiation
~~Note: Preferred Brand of recombinant factor VIII from 1 March 2016. When used in the treatment of haemophilia, funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.~~
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

28 NONACOG ALFA [RECOMBINANT FACTOR IX] (delisting)

➔ Inj 250 iu vial	310.00	1	BeneFIX
➔ Inj 500 iu vial	620.00	1	BeneFIX
➔ Inj 1,000 iu vial	1,240.00	1	BeneFIX
➔ Inj 2,000 iu vial	2,480.00	1	BeneFIX
➔ Inj 3,000 iu vial	3,720.00	1	BeneFIX

Note – BeneFIX inj 250 iu via, 500 iu vial, 1,000 iu vial, 2,000 iu vial and 3,000 iu vial to be delisted from 1 November 2019.

28 NONACOG GAMMA, [RECOMBINANT FACTOR IX] (↓ price and amended restriction criteria)

➔ Inj 500 iu vial	435.00	1	RIXUBIS
➔ Inj 1,000 iu vial	870.00	1	RIXUBIS
➔ Inj 2,000 iu vial	1,740.00	1	RIXUBIS
➔ Inj 3,000 iu vial	2,610.00	1	RIXUBIS

Restricted
Initiation
~~When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.~~
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

28 NONACOG GAMMA, [RECOMBINANT FACTOR IX] (delisted)

➔ Inj 250 iu vial	287.50	1	RIXUBIS

Note – RIXUBIS inj 250 iu vial delisted from 1 May 2019.

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 May 2019 (continued)

28 OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) (↓ price and amended restriction criteria)

➔ Inj 250 iu vial	210.00	1	Advate
➔ Inj 500 iu vial	420.00	1	Advate
➔ Inj 1,000 iu vial	840.00	1	Advate
➔ Inj 1,500 iu vial	1,260.00	1	Advate
➔ Inj 2,000 iu vial	1,680.00	1	Advate
➔ Inj 3,000 iu vial	2,520.00	1	Advate

Restricted
Initiation
~~Notes: Rare Clinical Circumstances Brand of recombinant factor VIII from 1 March 2016. When used in the treatment of haemophilia, access to funded treatment by application to the Haemophilia Treatments Panel. Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:~~

~~The Co-ordinator, Haemophilia Treatments Panel~~
~~PHARMAC PO Box 10 254~~
~~Wellington~~
~~Phone: 0800 023 588 Option 2~~
~~Facsimile: (04) 974 4881~~
~~Email: haemophilia@pharmac.govt.nz~~

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

29 OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) (amended restriction criteria)

➔ Inj 250 iu vial	237.50	1	Kogenate FS
➔ Inj 500 iu vial	475.00	1	Kogenate FS
➔ Inj 1,000 iu vial	950.00	1	Kogenate FS
➔ Inj 2,000 iu vial	1,900.00	1	Kogenate FS
➔ Inj 3,000 iu vial	2,850.00	1	Kogenate FS

Restricted
Initiation
~~Notes: Second Brand of recombinant factor VIII from 1 March 2016. When used in the treatment of haemophilia, access to funded treatment by application to the Haemophilia Treatments Panel. Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:~~

~~The Co-ordinator, Haemophilia Treatments Panel~~
~~PHARMAC PO Box 10 254~~
~~Wellington~~
~~Phone: 0800 023 588 Option 2~~
~~Facsimile: (04) 974 4881~~
~~Email: haemophilia@pharmac.govt.nz~~

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

29 RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] (new listing)

➔ Inj 250 iu vial	300.00	1	Adynovate
➔ Inj 500 iu vial	600.00	1	Adynovate
➔ Inj 1,000 iu vial	1,200.00	1	Adynovate
➔ Inj 2,000 iu vial	2,400.00	1	Adynovate

Restricted
Initiation
For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

INFECTIONS

72 ERTAPENEM (↓ price and addition of HSS)

➔ Inj 1 g vial – **1% DV Aug-19 to 2022**	70.00	1	**Invanz**

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 May 2019 (continued)

78 DOXYCYCLINE (new pack size)
Tab 100 mg ..... 64.43 500 Doxine

78 DOXYCYCLINE (delisting)
Tab 100 mg ..... 6.75 250 Doxine
Note – Doxine tab 100 mg, 250 tab pack to be delisted from 1 November 2019.

84 METRONIDAZOLE (pack size change)
Inj 5 mg per ml, 100 ml bag..... 264.00 48 Baxter
Note – Baxter inj 5 mg per ml, 100 ml bag, 10 inj pack to be delisted from 1 November 2019.

NERVOUS SYSTEM

104 LEVODOPA WITH CARBIDOPA (new listing)
Tab long-acting 100 mg with carbidopa 25 mg

105 BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE (↓ price and addition of HSS)
Inj 2.5 mg per ml with adrenaline 1:400,000,
20 ml vial – **1% DV Aug-19 to 2022** ..... 94.50 5 **Marcain with Adrenaline**

Inj 5 mg per ml with adrenaline 1:200,000,
20 ml vial – **1% DV Aug-19 to 2022** ..... 80.50 5 **Marcain with Adrenaline**

114 LAMOTRIGINE (↓ price and addition of HSS)
Tab dispersible 25 mg – **5% DV Oct-19 to 2022**..... 2.76 56 **Logem**
Tab dispersible 50 mg – **5% DV Oct-19 to 2022**..... 3.31 56 **Logem**
Tab dispersible 100 mg – **5% DV Oct-19 to 2022**..... 4.40 56 **Logem**

114 LAMOTRIGINE (delisting)
Tab dispersible 25 mg ..... 20.40 56 Arrow-Lamotrigine
29.09 Lamictal
Tab dispersible 50 mg ..... 34.70 56 Arrow-Lamotrigine
47.89 Lamictal
Tab dispersible 100 mg ..... 59.90 56 Arrow-Lamotrigine
79.16 Lamictal
Note – Arrow-Lamotrigine and Lamictal tab dispersible 25 mg, 50 mg and 100 mg to be delisted from 1 October 2019.

114 LEVETIRACETAM (↓ price and addition of HSS)
Tab 250 mg – **1% DV Aug-19 to 2022** ..... 4.99 60 **Everet**
Tab 500 mg – **1% DV Aug-19 to 2022** ..... 8.79 60 **Everet**
Tab 750 mg – **1% DV Aug-19 to 2022** ..... 14.39 60 **Everet**
Tab 1,000 mg – **1% DV Aug-19 to 2022** ..... 18.59 60 **Everet**

116 PIZOTIFEN (delisting)
Tab 500 mcg..... 23.21 100 Sandomigran
Note – Sandomigran tab 500 mcg (Pharmacode 251666) to be delisted from 1 November 2019.

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

Changes to Section H Part II – effective 1 May 2019 (continued)

VARIOUS

202 FLUMAZENIL (pack size change)
Inj 0.1 mg per ml, 5 ml ampoule – **1% DV Dec-18 to 2021** .... 132.68 10 **Hameln**
Note – Hameln inj 0.1 mg per ml, 5 ml ampoule, 5 inj pack to be delisted from 1 August 2019.

207 CHLORHEXIDINE WITH CETRIMIDE (new listing)
➔ Irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle

Restricted
Initiation
Re-assessment required after 3 months
All of the following:
1 Patient has burns that are greater than 30% of total body surface area (BSA); and
2 For use in the perioperative preparation and cleansing of large burn areas requiring debridement/skin grafting; and
3 The use of 30 ml ampoules is impractical due to the size of the area to be covered.

Continuation
Re-assessment required after 3 months
The treatment remains appropriate for the patient and the patient is benefiting from the treatment.

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

209 COMPOUND HYDROXYBENZOATE (new listing)
Soln – **1% DV Aug-19 to 2022** ..... 30.00 100 ml **Midwest**

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 April 2019

ALIMENTARY TRACT AND METABOLISM

17 CALCIUM CARBONATE (delisting delayed)
Tab eff 1.75 g (1 g elemental) ..... 2.07 10 Calsource
Note – Calsource tab eff 1.75 g (1 g elemental) delisting delayed from 1 July 2019 to 1 September 2019.

CARDIOVASCULAR SYSTEM

39 AMIODARONE HYDROCHLORIDE (HSS suspended)
Inj 50 mg per ml, 3 ml ampoule
– 1% DV Jun-17 to ~~2019~~ **31 March 2019** ..... 9.98 5 Lodi

39 AMIODARONE HYDROCHLORIDE (new listing)
Inj 50 mg per ml, 3 ml ampoule ..... 11.98 6 Cordarone-X

DERMATOLOGICALS

54 HYDROCORTISONE BUTYRATE (↑ price)
Crm 0.1% ..... 3.42 30 g Locoid Lipocream

INFECTIONS

72 IMIPENEM WITH CILASTATIN (addition of HSS)
➔ Inj 500 mg with 500 mg cilastatin
vial – **1% DV Jul-19 to 2022** ..... 60.00 1 **Imipenem + Cilastatin RBX**

86 EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL (new listing)
➔ Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) – **1% DV Jun-19 to 2022** .. 106.88 30 **Mylan**

86 EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL ~~FUMARATE~~ (amended chemical and presentation name and delisting)
➔ Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil **245 mg (**300 mg **as a** fumarate**)** ..... 237.52 30 Atripla
Note – Atripla to be delisted from 1 June 2019.

87 ATAZANAVIR SULPHATE (brand change)
➔ Cap 150 mg – **1% DV Jun-19 to 2022** ..... 141.68 60 **Teva**
➔ Cap 200 mg – **1% DV Jun-19 to 2022** ..... 188.91 60 **Teva**
Note – Reyataz cap 150 mg and 200 mg to be delisted from 1 June 2019.

90 EMTRICITABINE WITH TENOFOVIR DISOPROXIL (new listing)
➔ Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) – **1% DV Jun-19 to 2022** ..... 61.15 30 **Teva**

Changes to Section H Part II – effective 1 April 2019 (continued)

90 EMTRICITABINE WITH TENOFOVIR DISOPROXIL ~~FUMARATE~~ (amended chemical and presentation name and delisting)
➔ Tab 200 mg with tenofovir disoproxil **245 mg (**300 mg **as a** fumarate**)** ..... 190.02 30 Truvada
Note – Truvada to be delisted from 1 June 2019.

NERVOUS SYSTEM

109 LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (addition of HSS)
Spray 10% – **1% DV Jul-19 to 2022** ..... 75.00 50 ml **Xylocaine**

109 LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (↓ price and addition of HSS)
Inj 1%, 20 ml vial – **1% DV Jul-19 to 2022** ..... 6.20 5 **Lidocaine-Claris**
Inj 2%, 20 ml vial – **1% DV Jul-19 to 2022** ..... 6.45 5 **Lidocaine-Claris**

109 PRILOCAINE HYDROCHLORIDE (delisting)
Inj 2%, 5 ml ampoule ..... 55.00 10 Citanest
Note – Citanest inj 2%, 5 ml ampoule to be delisted from 1 October 2019.

119 METOCLOPRAMIDE HYDROCHLORIDE (↑ price)
Inj 5 mg per ml, 2 ml ampoule ..... 13.56 10 Pfizer

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

133 MERCAPTOPURINE (↓ price and addition of HSS)
Tab 50 mg – **1% DV Jul-19 to 2022** ..... 37.00 25 **Puri-nethol**

135 ETOPOSIDE (addition of HSS)
Cap 50 mg – **1% DV Jul-19 to 2022** ..... 340.73 20 **Vepesid**
Cap 100 mg – **1% DV Jul-19 to 2022** ..... 340.73 10 **Vepesid**

138 CARBOPLATIN (brand change)
Inj 10 mg per ml, 45 ml vial – **1% DV Jun-19 to 2021** ..... 45.20 1 **Carboplatin Ebewe**
Note – DBL Carboplatin inj 10 mg per ml,45 ml vial to be delisted from 1 June 2019.

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

212 GLYCERIN WITH SODIUM SACCHARIN (↓ price and addition of HSS)
Suspension – **1% DV Jul-19 to 2022** ..... 30.95 473 ml **Ora-Sweet SF**

212 GLYCERIN WITH SUCROSE (↓ price and addition of HSS)
Suspension – **1% DV Jul-19 to 2022** ..... 30.95 473 ml **Ora-Sweet**

212 METHYL HYDROXYBENZOATE (new listing)
Powder – **1% DV Jul-19 to 2022** ..... 8.98 25 g **Midwest**

212 METHYLCELLULOSE (new listing)
Powder – **1% DV Jul-19 to 2022** ..... 36.95 100 g **Midwest**

Changes to Section H Part II – effective 1 April 2019 (continued)

212 METHYLCELLULOSE (↓ price and addition of HSS)
Suspension – **1% DV Jul-19 to 2022**.....30.95 473 ml **Ora-Plus**

212 METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN (↓ price and addition of HSS)
Suspension – **1% DV Jul-19 to 2022**.....30.95 473 ml **Ora-Blend SF**

212 METHYLCELLULOSE WITH GLYCERIN AND SUCROSE (↓ price and addition of HSS)
Suspension – **1% DV Jul-19 to 2022**.....30.95 473 ml **Ora-Blend**

VACCINES

235 INFLUENZA VACCINE (Pharmacode change)
➔ Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) .....90.00 10 Influvac Tetra
Note – this is a new Pharmacode listing, 2558483. Pharmacode 2538466 to be delisted from 1 July 2019.

235 INFLUENZA VACCINE (amended restriction – affected criteria only shown)
➔ Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) ..9.00 1 Fluarix Tetra
Restricted
Initiation – Other conditions for patients aged 6 months to 35 months
~~Any of the following:~~
1 Any of the following:
1.1 Diabetes; or
1.2 Chronic renal disease; or
1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
1.4 Autoimmune disease; or
1.5 Immune suppression or immune deficiency; or
1.6 HIV; or
1.7 Transplant recipient; or
1.8 Neuromuscular and CNS diseases/ disorders; or
1.9 Haemoglobinopathies; or
1.10 Is a child on long term aspirin; or
1.11 Has a cochlear implant; or
1.12 Errors of metabolism at risk of major metabolic decompensation; or
1.13 Pre and post splenectomy; or
1.14 Down syndrome; or
1.15 Child who has been hospitalised for respiratory illness or has a history of significant respiratory illness~~;~~ ~~or~~
~~2 Child is living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board)~~

➔ Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) .....90.00 10 Influvac Tetra
Initiation – Other conditions for patients 3 years and over
~~Any of the following:~~ **Either:**
1 Any of the following:
1.1 Diabetes; or
1.2 chronic renal disease; or
1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
1.4 Autoimmune disease; or
1.5 Immune suppression or immune deficiency; or
1.6 HIV; or
1.7 Transplant recipient; or
1.8 Neuromuscular and CNS diseases/ disorders; or

continued...

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 April 2019 (continued)

continued...

1.9 Haemoglobinopathies; or
1.10 Is a child on long term aspirin; or
1.11 Has a cochlear implant; or
1.12 Errors of metabolism at risk of major metabolic decompensation; or
1.13 Pre and post splenectomy; or
1.14 Down syndrome; or
1.15 Is pregnant; or
1.16 Is a child aged four and under who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or

2 Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a DHB hospital~~; or~~

~~3 People under 18 years of age living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board)~~

Index
Pharmaceuticals and brands

Index
Pharmaceuticals and brands

New Zealand
Permit No. 478

Permit

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990
Fax: 64 4 460 4995
Website: www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3694 (Print)
ISSN 1179-3708 (Online)

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand